Loading...
Loading...
LPTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 13.2M |
| Operating I/L | -13.9M |
| Other Income/Expense | 2.0M |
| Interest Income | 0.5M |
| Pretax | -12.0M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -12.1M |
Leap Therapeutics, Inc. is a biopharmaceutical company specializing in acquiring and developing cancer therapies. Its primary focus is on DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, currently undergoing clinical trials for esophagogastric, hepatobiliary, gynecologic, and prostate cancers. The company generates revenue through the development and potential commercialization of DKN-01, with an option and license agreement in place with BeiGene, Ltd. for the Asian markets. This strategic partnership allows Leap Therapeutics to capitalize on the market potential of its lead clinical stage program, positioning the company for potential future revenue streams.
